(RTTNews) – GSK plc (GSK, GSK.L) introduced Thursday that the US Facilities for Illness Management and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to advocate use of Penmenvy (Meningococcal Teams A, B, C, W, and Y Vaccine) as a part of the adolescent meningococcal vaccination schedule.
The Committee voted to advocate that individuals over 10 years previous obtain a single dose of Penmenvy as a substitute for separate administration of meningococcal serogroups A, C, W and Y (MenACWY) and meningococcal serogroup B (MenB) vaccinations when each vaccines could be given on the identical clinic go to, usually at age 16.
This advice, if adopted, will permit for vaccination towards serogroups A, B, C, W and Y in fewer doses, might simplify meningococcal vaccination supply and will enhance immunisation charges, the corporate stated.
GSK’s MenABCWY vaccine combines the antigenic elements of the Firm’s two well-established meningococcal vaccines-Bexsero (Meningococcal Group B Vaccine) and Menveo (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine).
in February 2025, the US Meals and Drug Administration accredited GSK’s MenABCWY vaccine to be used in people aged 10 by way of 25 years.
For Extra Such Well being Information, go to rttnews.com.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
